Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (September 2025)
14 slides from Oncosil Medical's investor presentation, Sep 18, 2025
Slide 1: Investor Presentation September 2025
For personal use only Investor Presentation September, 2025 Nigel Lange, CEO & Managing Director ASX Code: OSL 1
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 3: Accelerating Commercialisation
Accelerating Commercialisation Compelling cost-benefit proposition with no direct competition • Average list price of ~€22k/~US$26k For personal use only Attractive Unit Economics • Gross Margin of 50% expected to increase to 65% driven by manufacturing productivity and targeting >75% device margins
Slide 4: Pancreatic Cancer Stage at Diagnosis
Pancreatic Cancer Stage at Diagnosis Surgical resection remains the only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC For personal use only % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curativ
Slide 5: OncoSil Device
OncoSil Device Achieves >90% local disease control with potential for downstaging1 For personal use only OncoSil is intended for the treatment of OncoSil is currently implanted locally advanced unresectable pancreatic directly into a pancreatic Percutaneous delivery is potentially cancer, in additio
Slide 6: Investigator Initiated Trial
PANCOSIL Investigator Initiated Trial Safety and feasibility of CT-guided percutaneous radionuclide therapy with the OncoSil For personal use only device in patients with non-progressive locally advanced pancreatic cancer (PANCOSIL): an open-label, single-arm phase 1-2 feasibility study To assess th
Slide 7: Investigator Initiated Trial
PANCOSIL Investigator Initiated Trial • Preliminary results presented at the Cardiovascular and Interventional Radiological For personal use only Society of Europe (CIRSE) Congress, one of the leading global forums for Interventional Radiology and Oncology. • Presented by Dr. Danielle Vos (Research
Slide 8: Study Design
PANCOSIL – Study Design 20 patients with unresectable LAPC and partial response or stable disease after at least 2 months of standard of care systemic treatment, considered eligible for inclusion For personal use only Study flowchart Baseline characteristics Demographic/Characteristic, n (%) unless
Slide 9: Preliminary Results
PANCOSIL – Preliminary Results Safety: For personal use only • No procedure-related mortality was observed. • Two (10%) of the 20 patients experienced CTCAE grade 3 serious adverse events within 90 days; one procedure- related and one possibly device-related. Both patients recovered. • There were no
Slide 10: Preliminary Results
PANCOSIL – Preliminary Results “The PANCOSIL study shows that percutaneous CT-guided implantation For personal use only of the OncoSil device is safe and feasible, while offering encouraging signals of clinical benefit. “This approach enables interventional radiologists to deliver the treatment with
Slide 11: Driving Adoption & Market Expansion
Driving Adoption & Market Expansion Expanding Clinical Adoption & Market Opportunity For personal use only Broadening the base of treating clinicians to include Interventional Radiologists (IRs) Strong alignment with IRs’ existing expertise in radiation-based therapies (e.g., Y-90) Enhanced
Slide 12: Upcoming Milestones & Execution Plan
Upcoming Milestones & Execution Plan Q2 FY26 – Full Clinical Results For personal use only Anticipated full data readout to reinforce clinical efficacy and safety profile Key inflection point to support reimbursement discussions and strengthen commercial positioning Risk mitigation: Active e
Slide 13: Upcoming Milestones
Upcoming Milestones Significant catalysts over the next 18 months For personal use only TGA Approval anticipated Label expansion to include Launch in SE Asia Completion of Percutaneous Delivery2 countries PANCOSIL Study TGA Submission HDE filling with FDA Launch in GCC for dCCA1 region 1H 2H 1H 2H C
Slide 14: Nigel Lange, CEO & Managing Director
For personal use only Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn
OncoSil Medical — Investor Presentation (September 2025) on 6ix